biotech
Bremelanotide Nasal Spray For Female Sexual Dysfunction Shows Favorable Phase IIa Trial Results
Filed in archive Drugs, Vaccines and Therapeutics by ruth on August 3, 2006
Bremelanotide Nasal Spray For Female Sexual Dysfunction Shows Favorable Phase IIa Trial Results
It took a backseat to drugs for Erectile Dysfunction in men, but Palatin Technologies, Inc. (AMEX: PTN) and King Pharmaceuticals, Inc. (NYSE: KG) seems to be making headway with a nasal spray designed to treat female sexual arousal disorder (FSAD) in post-menopausal women. Phase IIa
pilot studies involving 26 patients diagnosed with FSAD showed favorable results.
Results showed that on a 14-item questionnaire, 73 percent of the women reported an increased level of genital arousal while on bremelanotide compared with 23 percent of women on placebo. Also, 46 percent of women on bremelanotide reported an increased level of sexual desire while only 19 percent of women responded similarly after placebo treatment. Additionally, subjects receiving bremelanotide reported a higher incidence of engaging in sexual activity compared to placebo.

Bremelanotide, the active ingredient in the nasal spray, is the first compound in a new drug class called melanocortin receptor agonists under development to treat sexual dysfunction.The companies are now enrolling patients for an larger Phase IIb trials throughout the US.

Permalink: Bremelanotide Nasal Spray For Female Sexual Dysfunction Shows Favorable Phase IIa Trial Results
Tags: sexual  menopause  biotech  phase  bremelanotide  sexual+dysfunction  trial+results  female+sexual 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/31022
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Bremelanotide Nasal Spray For Female Sexual Dysfunction Shows Favorable Phase IIa Trial Results:

  • Currently 8.33/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 8.33 out of 9 vote(s) cast.
 
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!